How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
26
11
2019
medline:
15
12
2020
entrez:
26
11
2019
Statut:
ppublish
Résumé
The extrapolation of estimated hazard functions can be an important part of cost-effectiveness analyses. Given limited follow-up time in the sample data, it may be expected that the uncertainty in estimates of hazards increases the further into the future they are extrapolated. The objective of this study was to illustrate how the choice of parametric survival model impacts on estimates of uncertainty about extrapolated hazard functions and lifetime mean survival. We examined seven commonly used parametric survival models and described analytical expressions and approximation methods (delta and multivariate normal) for estimating uncertainty. We illustrate the multivariate normal method using case studies based on four representative hypothetical datasets reflecting hazard functions commonly encountered in clinical practice (constant, increasing, decreasing, or unimodal), along with a hypothetical cost-effectiveness analysis. Depending on the survival model chosen, the uncertainty in extrapolated hazard functions could be constant, increasing or decreasing over time for the case studies. Estimates of uncertainty in mean survival showed a large variation (up to sevenfold) for each case study. The magnitude of uncertainty in estimates of cost effectiveness, as measured using the incremental cost per quality-adjusted life-year gained, varied threefold across plausible models. Differences in estimates of uncertainty were observed even when models provided near-identical point estimates. Survival model choice can have a significant impact on estimates of uncertainty of extrapolated hazard functions, mean survival and cost effectiveness, even when point estimates were similar. We provide good practice recommendations for analysts and decision makers, emphasizing the importance of considering the plausibility of estimates of uncertainty in the extrapolated period as a complementary part of the model selection process.
Sections du résumé
BACKGROUND AND OBJECTIVE
The extrapolation of estimated hazard functions can be an important part of cost-effectiveness analyses. Given limited follow-up time in the sample data, it may be expected that the uncertainty in estimates of hazards increases the further into the future they are extrapolated. The objective of this study was to illustrate how the choice of parametric survival model impacts on estimates of uncertainty about extrapolated hazard functions and lifetime mean survival.
METHODS
We examined seven commonly used parametric survival models and described analytical expressions and approximation methods (delta and multivariate normal) for estimating uncertainty. We illustrate the multivariate normal method using case studies based on four representative hypothetical datasets reflecting hazard functions commonly encountered in clinical practice (constant, increasing, decreasing, or unimodal), along with a hypothetical cost-effectiveness analysis.
RESULTS
Depending on the survival model chosen, the uncertainty in extrapolated hazard functions could be constant, increasing or decreasing over time for the case studies. Estimates of uncertainty in mean survival showed a large variation (up to sevenfold) for each case study. The magnitude of uncertainty in estimates of cost effectiveness, as measured using the incremental cost per quality-adjusted life-year gained, varied threefold across plausible models. Differences in estimates of uncertainty were observed even when models provided near-identical point estimates.
CONCLUSIONS
Survival model choice can have a significant impact on estimates of uncertainty of extrapolated hazard functions, mean survival and cost effectiveness, even when point estimates were similar. We provide good practice recommendations for analysts and decision makers, emphasizing the importance of considering the plausibility of estimates of uncertainty in the extrapolated period as a complementary part of the model selection process.
Identifiants
pubmed: 31761997
doi: 10.1007/s40273-019-00853-x
pii: 10.1007/s40273-019-00853-x
pmc: PMC6976548
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
193-204Subventions
Organisme : Department of Health
ID : DRF-2016-09-119
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0902159
Pays : United Kingdom
Références
J Stat Softw. 2016 May 12;70:null
pubmed: 29593450
Pharmacoeconomics. 2017 Dec;35(12):1257-1270
pubmed: 28866758
Stat Med. 2007 Oct 15;26(23):4352-74
pubmed: 17342754
Med Decis Making. 2019 Oct;39(7):867-878
pubmed: 31556792
Pharmacoeconomics. 2013 Jun;31(6):479-88
pubmed: 23580356
Pharmacoeconomics. 2016 May;34(5):447-61
pubmed: 26753558
Med Decis Making. 2013 Apr;33(3):369-80
pubmed: 23457025
Stat Med. 2002 Aug 15;21(15):2175-97
pubmed: 12210632
Stat Med. 2008 Sep 20;27(21):4301-12
pubmed: 18407568
Stat Med. 2019 May 20;38(11):2074-2102
pubmed: 30652356
Pharmacoeconomics. 2013 Aug;31(8):663-75
pubmed: 23673905
Pharmacoeconomics. 2018 Oct;36(10):1135-1141
pubmed: 29926358
BMC Med. 2016 Dec 6;14(1):200
pubmed: 27919292
Med Decis Making. 2014 Apr;34(3):343-51
pubmed: 23901052
Stat Med. 1998 Apr 30;17(8):813-30
pubmed: 9595613
Pharmacoeconomics. 2013 Aug;31(8):643-52
pubmed: 23807751
Med Decis Making. 2013 Aug;33(6):743-54
pubmed: 23341049
Pharmacoeconomics. 2017 Sep;35(9):867-877
pubmed: 28616775